{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:09Z","timestamp":1791919689457,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.coi.2022.102210","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:11:33Z","timestamp":1653437493000},"page":"102210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Viral vector vaccines"],"prefix":"10.1016","volume":"77","author":[{"given":"Naina","family":"McCann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2022.102210_bib1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.coi.2022.102210_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.coi.2022.102210_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-label phase I clinical trial of Ad5-EBOV in Africans in China","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coi.2022.102210_bib6","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.coi.2022.102210_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"389","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.coi.2022.102210_bib9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a Trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2022.102210_bib10","article-title":"An open, non-randomised, phase 1\/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine \u201cSputnik Light\u201d for prevention of coronavirus infection in healthy adults","volume":"11","author":"Tukhvatulin","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.coi.2022.102210_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_sbref12","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib14","doi-asserted-by":"crossref","first-page":"P505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"389","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib15","doi-asserted-by":"crossref","first-page":"P857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"386","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib16","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2022.102210_bib17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese Encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese Encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.coi.2022.102210_bib19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2022.102210_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib22","doi-asserted-by":"crossref","first-page":"P887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.coi.2022.102210_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ofid\/ofv131.97","article-title":"Heterologous prime-boost schedules of replication-defective adenovirus serotype 26 and modified vaccinia virus ankara vector vaccines expressing ebola virus glycoprotein are immunogenic and well tolerated in healthy adults","volume":"2","author":"Milligan","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib25","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.coi.2022.102210_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_sbref27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/JVI.01926-06","article-title":"Preferential activation of toll-like receptor nine by CD46-utilizing adenoviruses","volume":"81","author":"Iacobelli-Martinez","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2022.102210_bib30","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.685218","article-title":"Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes","volume":"12","author":"Ch\u00e9neau","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2022.102210_bib33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.mt.6300024","article-title":"Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector","volume":"15","author":"Hensley","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2022.102210_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coi.2022.102210_sbref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-021-08061-8","article-title":"Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen","volume":"22","author":"Sheerin","year":"2021","journal-title":"BMC Genom"},{"key":"10.1016\/j.coi.2022.102210_sbref37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579872","article-title":"Innate immune responses to chimpanzee adenovirus vector 155 vaccination in mice and monkeys","volume":"11","author":"Collignon","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib38","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8 + T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2022.102210_bib39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2022.102210_bib40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.coi.2022.102210_bib41","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/infdis\/jiaa460","article-title":"Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine","volume":"223","author":"Jordan","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2022.102210_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coi.2022.102210_bib44","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2022.102210_bib45","article-title":"SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers","author":"Wyllie","year":"2021","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.coi.2022.102210_bib46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.coi.2022.102210_bib47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.coi.2022.102210_bib48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41423-022-00838-5","article-title":"T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant","volume":"19","author":"Choi","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib49","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2022.102210_sbref50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coi.2022.102210_bib51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.coi.2022.102210_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.coi.2022.102210_bib53","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.coi.2022.102210_bib54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"Immunogenicity, lot consistency, and extended safety of rVSV\u0394G-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_sbref56","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2022.102210_bib57","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2022.102210_bib58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_sbref59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2022.102210_bib60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coi.2022.102210_bib61","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010016","article-title":"Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials","volume":"17","author":"Fischinger","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2022.102210_sbref63","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.aax8819","article-title":"MAIT cell activation augments adenovirus vector vaccine immunogenicity","volume":"371","author":"Provine","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coi.2022.102210_sbref64","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2022.102210_bib65","doi-asserted-by":"crossref","first-page":"P1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib66","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib67","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib68","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2022.102210_bib69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib70","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","article-title":"Novel prime-boost vaccine strategies against HIV-1","volume":"18","author":"Excler","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2022.102210_bib73","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2022.102210_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-021-00246-9","article-title":"Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people","volume":"18","author":"Parry","year":"2021","journal-title":"Immun Ageing"},{"key":"10.1016\/j.coi.2022.102210_bib75","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus Type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2022.102210_bib76","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib77","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2022.102210_bib78","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2022.102210_bib79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/CVI.00418-07","article-title":"Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses","volume":"15","author":"Geiben-Lynn","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2022.102210_bib80","doi-asserted-by":"crossref","first-page":"P856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib81","doi-asserted-by":"crossref","first-page":"P36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib82","doi-asserted-by":"crossref","first-page":"P121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2022.102210_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice","volume":"12","author":"Spencer","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2022.102210_bib84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/vaccines9090959","article-title":"Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen","volume":"9","author":"G\u00f3mez","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.coi.2022.102210_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14760584.2020.1711054","article-title":"The potential of adenoviral vaccine vectors with altered antigen presentation capabilities","volume":"19","author":"Neukirch","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2022.102210_bib86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines8010064","article-title":"Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope","volume":"8","author":"Matchett","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.coi.2022.102210_sbref87","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/s41598-020-61730-8","article-title":"Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule","volume":"10","author":"Rollier","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2022.102210_bib88","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-controlled trial of two vaccines to prevent Ebola in liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2022.102210_bib89","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JVI.02184-14","article-title":"Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines","volume":"89","author":"Crosby","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2022.102210_bib90","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiy411","article-title":"A replicating single-cycle adenovirus vaccine against Ebola virus","volume":"218","author":"Anguiano-Zarate","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2022.102210_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00976-18","article-title":"Newcastle disease virus-based vectored vaccine against poliomyelitis","volume":"92","author":"Viktorova","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2022.102210_bib92","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2022.102210_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00545-3","article-title":"Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination","volume":"10","author":"Soboleva","year":"2022","journal-title":"Lancet Glob Health"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791522000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791522000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:47:31Z","timestamp":1760604451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791522000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":93,"alternative-id":["S0952791522000577"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2022.102210","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vector vaccines","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2022.102210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102210"}}